<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24064978</article-id><article-id pub-id-type="pmc">3817325</article-id><article-id pub-id-type="pii">bjc2013582</article-id><article-id pub-id-type="doi">10.1038/bjc.2013.582</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reply to Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Reply: &#x02018;Comment on Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery <italic>vs</italic> radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)'</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Katsumata</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, 1-396, Kosugi-machi</institution>, Nakahara-ku, Kawasaki-city, Kanagawa prefecture 211-8533, <country>Japan</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>nkatsuma@nms.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><day>29</day><month>10</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>24</day><month>09</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>10</month><year>2013</year></pub-date><volume>109</volume><issue>9</issue><fpage>2506</fpage><lpage>2506</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions></article-meta></front><body><p><bold>Sir,</bold></p><p>We would like to thank <xref ref-type="bibr" rid="bib3">Nagano (2013)</xref> for their comments on our work, and take this opportunity to respond to the points they raise in their letter. If adjuvant radiotherapy had been given to all patients who received neoadjuvant chemotherapy regardless of the surgical findings, the neoadjuvant therapy might be better. However, the radiation-related morbidity will not reduce. Because the purpose of neoadjuvant chemotherapy is not only to improve survival but also to reduce surgical morbidity, postoperative irradiation, and radiation-related morbidity, recent neoadjuvant trials including our trial were designed that postoperative radiotherapy was delivered if patients had high-risk factors for recurrence (<xref ref-type="bibr" rid="bib4">Napolitano <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="bib1">Cai <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib2">Eddy <italic>et al</italic>, 2007</xref>).</p><p>The trials of neoadjuvant chemotherapy are still ongoing. We need more potent chemotherapy to get more efficacies. Further trials including paclitaxel and/or bevacizumab are warranted to clarify potential benefits of neoadjuvant chemotherapy for cervical cancer.</p></body><back><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>HB</given-names></name><name><surname>Chen</surname><given-names>HZ</given-names></name><name><surname>Yin</surname><given-names>HH</given-names></name></person-group><year>2006</year><article-title>Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer</article-title><source>J Obstet Gynaecol Res</source><volume>32</volume><supplement>(3</supplement><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">16764623</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>GL</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name><name><surname>Spirtos</surname><given-names>NM</given-names></name><name><surname>Mannel</surname><given-names>RS</given-names></name><name><surname>Hannigan</surname><given-names>E</given-names></name><etal/></person-group><year>2007</year><article-title>Treatment of (&#x02018;bulky') stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group</article-title><source>Gynecol Oncol</source><volume>106</volume><supplement>(2</supplement><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">17493669</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagano</surname><given-names>H</given-names></name></person-group><year>2013</year><article-title>Comment on &#x02018;Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery <italic>vs</italic> radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)'</article-title><source>Br J Cancer</source><volume>109</volume><fpage>2505</fpage><pub-id pub-id-type="pmid">24064973</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>U</given-names></name><name><surname>Imperato</surname><given-names>F</given-names></name><name><surname>Mossa</surname><given-names>B</given-names></name><name><surname>Framarino</surname><given-names>ML</given-names></name><name><surname>Marziani</surname><given-names>R</given-names></name><name><surname>Marzetti</surname><given-names>L</given-names></name></person-group><year>2003</year><article-title>The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial</article-title><source>Eur J Gynaecol Oncol</source><volume>24</volume><supplement>(1</supplement><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">12691318</pub-id></mixed-citation></ref></ref-list></back></article>